Skip to Content
Merck

Key Documents

View All Documentation

N4382

Nalidixic acid sodium salt

DNA gyrase inhibitor, powder

Synonym(s):

1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid sodium salt

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C12H11N2NaO3
CAS Number:
3374-05-8
Molecular Weight:
254.22
NACRES:
NA.77
PubChem Substance ID:
24278589
UNSPSC Code:
12352106
EC Number:
222-159-7
MDL number:
MFCD00064376
Beilstein/REAXYS Number:
3580062
Form:
powder
Quality level:
200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Nalidixic acid sodium salt, powder

form

powder

Quality Level

200

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria

mode of action

DNA synthesis | interferes, enzyme | inhibits

originator

Sanofi Aventis

SMILES string

[Na+].CCN1C=C(C([O-])=O)C(=O)c2ccc(C)nc12

InChI

1S/C12H12N2O3.Na/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14;/h4-6H,3H2,1-2H3,(H,16,17);/q;+1/p-1

InChI key

ROKRAUFZFDQWLE-UHFFFAOYSA-M

General description

Nalidixic acid is a quinolone and can block the activity of bacterial topoisomerase type II enzyme, thereby stopping bacterial replication. It is a potential antibacterial agent against Gram-negative bacteria than Gram-positive bacteria. Nalidixic acid has been studied in the management of urinary tract infections.
Chemical structure: quinolone

Application

Nalidixicacid has been used to treat the bacterial cultures to study itsresistance on Salmonella enterica and SalmonellaTyphimurium.

Biochem/physiol Actions

Nalidixic acid sodium salt is an inhibitor of bacterial DNA polymerase (DNA gyrase) and avian myeloblastoma virus reverse transcriptase. Inhibits nucleic acid and protein synthesis in Saccharomyces cerevisiae.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Nalidixic acid sodium salt

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H351

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
1417277
107K0714
106K0709
073H5058
061K5303

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Crystal Y Chen et al.
PLoS pathogens, 5(4), e1000392-e1000392 (2009-04-22)
The role of CD8 T cells in anti-tuberculosis immunity in humans remains unknown, and studies of CD8 T cell-mediated protection against tuberculosis in mice have yielded controversial results. Unlike mice, humans and nonhuman primates share a number of important features
Margarita A Arreguin-Nava et al.
Animals : an open access journal from MDPI, 9(9) (2019-09-20)
The effect of Lactobacillus spp.-based probiotic candidates on Salmonella enterica serovar Enteritidis (SE) colonization was evaluated in two separate experiments. In each experiment, sixty-one day-of-hatch female turkey poults were obtained from a local hatchery. In both experiments, poults were challenged
Michelle H Larsen et al.
Vaccine, 27(34), 4709-4717 (2009-06-09)
Tuberculosis (TB) remains a global health burden for which safe vaccines are needed. BCG has limitations as a TB vaccine so we have focused on live attenuated Mycobacterium tuberculosis mutants as vaccine candidates. Prior to human studies, however, it is
View All Related Papers